Navigation Links
Targeted Genetics Reports on Recombinant DNA Advisory Committee (RAC) Review of its Phase 1/2 Trial of tgAAC94 for Rheumatoid Arthritis
Date:9/17/2007

the study will continue to be followed and monitored. Since the trial began in October 2005, 127 subjects have received an initial dose of active drug or placebo into the knee, ankle, wrist, metacarpophalangeal or elbow, and 74 subjects out of the total 127 have received a second dose of active drug. Of those 74 subjects, 55 have received two doses of active drug.

Conference Call and Webcast Information

The Company will host a conference call to discuss the RAC review tomorrow beginning at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. You may access the live webcast via the "Events" section found on the Homepage of the Company's website at http://www.targetedgenetics.com or via telephone at 800-240-2430 (domestic) or 303-262-2131 (international).

Replay Access

Webcast replay will be available for approximately 30 days at http://www.targetedgenetics.com; telephone replay will be available approximately one hour following Tuesday's call through 11:59 p.m. PT, Tuesday, October 30, 2007, by calling 800.405.2236 (domestic) or 303.590.3000 (international); pass code 11097397#.

About Targeted Genetics

Targeted Genetics Corporation is a biotechnology company committed to the development of innovative targeted molecular therapies for the prevention and treatment of acquired and inherited diseases with significant unmet medical need. Targeted Genetics' proprietary Adeno-Associated Virus (AAV) technology platform allows it to deliver genes that encode proteins to increase gene function or RNAi to decrease or silence gene function. Targeted Genetics' product development efforts target inflammatory arthritis, AIDS prophylaxis, congestive heart failure and Huntington's disease. To learn more about Targeted Genetics, visit Targeted Genetics' website at http://www.targe
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma
4. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
7. News from the Battlefield of Metastatic Cancer: Epeius Biotechnologies Draws the Sword of Targeted Gene Delivery (Rexin-G) from the Stone of Chemistry and Physics
8. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
9. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
10. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Sept. 19, 2014  Today DePuy Synthes Companies ... angle plating systems featuring its proprietary variable angle ... screw trajectory to match patient anatomy and fracture ... bone. The systems are being introduced in conjunction ... (AOFAS) and the International Federation of Foot & ...
(Date:9/19/2014)... /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... report firstly reviews the basic information of ... manufacturing technology. The report then explores global ... listing their product specification, capacity, Production value, ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
Breaking Medicine Technology:DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3
... March 5, 2012   Synteract , Inc., a full-service contract ... MBA, as senior vice president of sales and marketing and ... president, global project management, to support growth in the company ... Barr, COO Stewart Bieler, and CFO Patrik Jeanmonod on the ...
... Checkpoint Surgical has received the CE mark ... intraoperative neuroprotective stimulator that helps surgeons locate, identify ... to facilitate nerve preservation and repair. ... certification demonstrates that a medical device meets rigorous ...
Cached Medicine Technology:Synteract Expands Executive Roles to Support Growth 2Synteract Expands Executive Roles to Support Growth 3Checkpoint Surgical Receives CE Mark 2
(Date:9/21/2014)... PITTSBURGH, PA (PRWEB) September 21, 2014 ... energy boost without having to consume sugary, foul-tasting energy ... also did not always just want to drink plain, ... this alternative energy booster." , He developed ENERG CHEWING ... also assist with weight loss. The formula contains nutritious ...
(Date:9/21/2014)... 2014 "I want to help people ... but haven’t the money for chiropractors," said an inventor ... such a product for myself." , The Stretch is ... the thigh muscles and align the spine properly. It ... discomfort of pinched nerves. Compact and easy to use, ...
(Date:9/21/2014)... 2014 Best Cheap Hosting USA, one ... Arvixe, Bluehost and GreenGeeks are the best Reseller hosting ... good reseller hosting supplier. Actually, these companies have outperformed ... customer support. People can get the best web hosting ... , According to the manager, reseller hosting is a ...
(Date:9/21/2014)... To accommodate the ever-growing customer base, Angeldress.co.uk ... trendy items. Recently, the company has unveiled its 2014 ... and elegant wedding gowns, Angeldress.co.uk wants to make sure ... an easy way. Its high quality vintage wedding outfits ... off to 62% off. , Online shopping is becoming ...
(Date:9/21/2014)... 2014 “Cluster headaches are sometimes called ... difficult to resolve,” said Steve Young of Ew Publishing; ... a pain that is more intense.” , “It should ... headaches, or migraines, that medical research is pointing to ... he added. , Serotonin (5-HT, 5-hydroxytryptamine) is a ubiquitous ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Announces The Best Reseller Hosting Suppliers In 2014 2Health News:Angeldress.co.uk Launches New Range Of 2014 Vintage Wedding Dresses In Its Online Store 2Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2
... Ga., April 30 Immucor, Inc. (Nasdaq: ... systems to the blood transfusion industry, today announced that ... and Merrill Lynch 2009 Health Care Conference in New ... webcast. The Company,s presentation is scheduled for Tuesday, ...
... - Clinic operations revenue ... sales revenue increases 173%,VANCOUVER, April 30 /PRNewswire-FirstCall/ - CRH ... of $6,655,342 for the year ended 2008 compared to ... operations revenue increased 100% to $6,047,590 for the year ...
... proven calcium channel blocker, angiotensin receptor blocker and ... In a clinical trial, Exforge HCT demonstrated significantly ... to all dual combinations of its components - ... medications to help control their blood pressure and ...
... /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") ... markets specialty pharmaceutical products in China, today announced ... Company on investor communications best-practices in the U.S. ... China Pharma, stated, "Our decision to hire ICR ...
... added benefit from cholesterol-reducing agent , , , THURSDAY, ... cells to release cholesterol might prove effective in ... new study suggests. , George Washington University researchers ... found that the treatment restored cholesterol outflow from ...
... HealthSouth Corporation (NYSE: HLS ) today announced it ... Conference on May 12-14, 2009, at the Four Seasons Hotel ... Executive Vice President and Chief Financial Officer John Workman will ... (7:55 a.m. CT). The presentation will be webcast live and ...
Cached Medicine News:Health News:CRH Medical reports year end results 2Health News:CRH Medical reports year end results 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 2Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 3Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 4Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 5Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 6Health News:Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill 7Health News:China Pharma Holdings, Inc. Retains Global Investor Communications Team 2
... Design Holds The Lens Securely During ... Blades Keep The Optic From Being ... Over Release Of The Optic.,Wide Jaw ... During Insertion.,Reusable, Autoclaveable, Made In The ...
... Unique In-Line Footplates Are Turned 90 ... The Diamond Blade While Incising Tissue. ,Special ... Blade Depth Penetration.,Pre-Set Blade Extension Settings ... Retraction And Full Extension.,1mm Wide Snub ...
2.5V Halogen source, fiber-optic delivery, 2.5X magnification....
Pocket-sized instrument with 2.5X magnification....
Medicine Products: